Advanced Cancer Pain Management Pipeline Insight 2023

PRESS RELEASE

Published May 23, 2023

DelveInsight’s, “Advanced Cancer Pain Management Pipeline Insights 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Advanced Cancer Pain Management pipeline landscape. It covers the Advanced Cancer Pain Management pipeline drug profiles, including Advanced Cancer Pain Management clinical trials and nonclinical stage products. It also covers the Advanced Cancer Pain Management therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

 Key Takeaways from the Advanced Cancer Pain Management Pipeline Report

 

  • DelveInsight’s Advanced Cancer Pain Management Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Advanced Cancer Pain Management treatment.

 

  • The leading Advanced Cancer Pain Management Companies include Tetra Bio-Pharma, Medlab, Sorrento Therapeutics Inc, Pfizer, Jazz Pharmaceuticals, Otsuka Pharmaceuticals, and Others

 

  • Promising Advanced Cancer Pain Management Pipeline Therapies include Nabiximols, Placebo (GA-0034), QIXLEEF, NanaBis, and others

 

  • Advanced Cancer Pain Management companies and academics are working to assess challenges and seek opportunities that could influence Advanced Cancer Pain Management R&D. The Advanced Cancer Pain Management therapies under development are focused on novel approaches to treat/improve Advanced Cancer Pain Management.

 

Request a sample and discover the recent breakthroughs happening in the Advanced Cancer Pain Management Pipeline landscape @ Advanced Cancer Pain Management Pipeline Outlook

 

Advanced Cancer Pain Management Overview

Advanced Cancer Pain is the pain most commonly experienced and feared by patients with advanced cancer, during their treatment. Pain in a cancer patient is a subjective, multi-dimensional human experience, with complex interactions between sensory and emotional components. Twenty to 34 percent of patients have severe pain, which directly influences their quality of life and daily function (i.e., pain interference). Solid tumors produce more pain than leukemias and lymphomas. Most cancer patients experience pain, usually of moderate to severe intensity, and most also have a number of distinct pains.

 

Advanced Cancer Pain Management Emerging Drugs Profile

 

  • QIXLEEF: Tetra Bio-Pharma

QIXLEEF™ is a cannabinoid-derived medicines developed by Tetra Bio-pharma for the treatment of uncontrolled pain in advanced cancer patients. It is a first-generation, Cannabinoid receptor agonists and is derived from a dried cannabis flower bud. QIXLEEF™ contains no excipients or other nonmedicinal ingredients. It has a safe and well tolerated profile along with a rapid and high degree of absorption favoring a higher efficacy at a lower dose, compared to oral administration.

 

NanaBis is the Medlab’s cannabis-based pain management product, comprised of a proprietary 1:1 blend of highly purified cannabidiol (CBD) and tetrahydrocannabinol (THC) molecules. NanaBis is developed as a pain management alternative to traditional opioids—particularly for patients suffering from advanced types of cancer and chronic pain. In the Phase 1 clinical trial result, it was safe, tolerable, and efficacious and the dosage tolerance was achieved at 60% of the maximum dosage.

 

For further information, refer to the detailed Advanced Cancer Pain Management Drugs Launch, Advanced Cancer Pain Management Developmental Activities, and Advanced Cancer Pain Management News, click here for Advanced Cancer Pain Management Ongoing Clinical Trial Analysis

 

Advanced Cancer Pain Management Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Advanced Cancer Pain Management (ACPM). The companies which have their Advanced Cancer Pain Management (ACPM) drug candidates in the most advanced stage, i.e. phase III include, Tetra Bio-Pharma.

 

Advanced Cancer Pain Management Pipeline Segmentation

 

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Advanced Cancer Pain Management (ACPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Find out more about the Advanced Cancer Pain Management Pipeline Segmentation, Therapeutics Assessment, and Advanced Cancer Pain Management Emerging Drugs @ Advanced Cancer Pain Management Treatment Landscape

 

Scope of the Advanced Cancer Pain Management Pipeline Report

 

 

  • Advanced Cancer Pain Management Companies- Tetra Bio-Pharma, Medlab, Sorrento Therapeutics Inc, Pfizer, Jazz Pharmaceuticals, Otsuka Pharmaceuticals, and Others

 

  • Advanced Cancer Pain Management Pipeline Therapies- Nabiximols, Placebo (GA-0034), QIXLEEF, NanaBis, and others

 

  • Advanced Cancer Pain Management Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Advanced Cancer Pain Management Pipeline Companies and Therapies, click here @ Advanced Cancer Pain Management Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Cancer Pain Management (ACPM): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Cancer Pain Management (ACPM) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Advanced Cancer Pain Management (ACPM) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. QIXLEEF: Tetra Bio-Pharma
  11. Early Stage Products (Phase I)
  12. NanaBis: Medlab
  13. Inactive Products
  14. Advanced Cancer Pain Management (ACPM) Key Companies
  15. Advanced Cancer Pain Management (ACPM) Key Products
  16. Advanced Cancer Pain Management (ACPM)- Unmet Needs
  17. Advanced Cancer Pain Management (ACPM)- Market Drivers and Barriers
  18. Advanced Cancer Pain Management (ACPM)- Future Perspectives and Conclusion
  19. Advanced Cancer Pain Management (ACPM) Analyst Views
  20. Advanced Cancer Pain Management (ACPM) Key Companies
  21. Appendix

 

Got Queries? Find out the related information on Advanced Cancer Pain Management Mergers and acquisitions, Advanced Cancer Pain Management Licensing Activities @ Advanced Cancer Pain Management Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *